NCT06492187 Triage Survey for Infectious Disease Eligibility
| NCT ID | NCT06492187 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brooklyn Clinical Research |
| Condition | Vaccination; Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-06-28 |
| Primary Completion | 2029-01-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-06-28 with a primary completion date of 2029-01-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
SWIFT-ID-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials for diagnosis, treatment, or prevention of infectious diseases such as in the areas of HIV, vaccines, and other infectious-diseases areas. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical/surgical history, physical examination, comorbidities, and any current symptoms. Informed consent will be done electronically (preferable) or on paper. Informed consent may be done in-person or remotely, depending on patient preference. Information related to HIV, hepatitis B and C, other infectious diseases, or substance use disorder will also be obtained if applicable. Site staff may collect vital signs, fingerpick testing, urine drug screens, blood draws, EKG, and pregnancy tests. Some testing may be recommended in a fasting condition. A doctor will review medical history and results of the above evaluations with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians, other providers, and pharmacies to determine eligibility for clinical trials. A follow-up phone call may be needed to discuss testing results and/or trial eligibility. If a participant is deemed eligible for future trials and if the participant remains interested, counseling on contraception requirements for trials will be discussed.
Eligibility Criteria
Inclusion Criteria: \- 1. Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed. 2\. Participant is at least 18 years old. Exclusion Criteria: 1. Participants are pregnant, breast-feeding, or planning to become pregnant. 2. History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results or makes them unsuitable for the study for another reason. 3. Current or recent moderate or severe substance use disorder impacting their ability to follow study related procedures. 4. Reported history of coagulopathy or bleeding disorder considered a contraindication to phlebotomy. 5. Any condition that in the investigator's opinion makes a participant unsuitable for the clinical trial study. 6. Currently employed by Swift Clinical Research Group, Inc. or any of its subsidiaries, including Brooklyn Clinical Research, or a first-degree relative of an employee.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06492187 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Vaccination; Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06492187 currently recruiting?
Yes, NCT06492187 is actively recruiting participants. Contact the research team at amushtaq@brooklynclinicalresearch.com for enrollment information.
Where is the NCT06492187 trial being conducted?
This trial is being conducted at Brooklyn, United States.
Who is sponsoring the NCT06492187 clinical trial?
NCT06492187 is sponsored by Brooklyn Clinical Research. The trial plans to enroll 10,000 participants.